Mariano Barbacid - Curriculum vitae and biography#


EDUCATION AND TRAINING
  • 1966-1971 Graduated in Chemical Sciences (Biochemistry), Universidad Complutense, Madrid
  • 1971-1974 Ph.D. in Biochemistry, Universidad Complutense, Madrid
    Thesis carried out at Instituto de Biología Celular, C.S.I.C. (Spanish Research Council), Madrid
  • 1974-1977 Postdoctoral Fellow, National Cancer Institute, NIH, Bethesda, Maryland

Fellowships
  • 1971-1974 "Beca de Formación de Personal Investigador" (PhD Training Programme), "Ministerio de Educación y Ciencia", Spain
  • 1974-1975 Postdoctoral Fellow, USA-Spain Exchange Program
  • 1975-1977 Visiting Fellow, National Cancer Institute, NIH.

EMPLOYMENT
  • 1978-1984 Visiting Scientist, National Cancer Institute, NIH, Bethesda, Maryland, USA
  • 1984-1988 Head, Developmental Oncology Section, Basic Research Program, NCI-FCRF, Frederick, Md, USA
  • 1988-1992 Executive Director, Department of Molecular Biology, Bristol-Myers Squibb Pharm. Research Institute (BMSPRI), Princeton, New Jersey, USA.
  • 1992-1995 Vice President, Molecular Biology, BMSPRI, Princeton, New Jersey, USA.
  • 1992-1998 Vice President, Oncology Drug Discovery, BMSPRI, Princeton, New Jersey, USA.
  • 1998-Present Director, Centro Nacional de Investigaciones Oncológicas (CNIO)(Spanish National Cancer Research Center), Madrid, Spain

OTHER APPOINTMENTS
  • 1974-1984 "Colaborador Científico", C.S.I.C. Madrid, Spain
  • 1984-Present "Profesor de Investigación", C.S.I.C., Madrid, Spain (On leave of absence)
  • 1993-1998 Visiting Professor, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA
  • 1995-1998 Adjunct Professor, Department of Biochemistry, Robert Wood Johnson Medical School, UMDNJPiscataway, New Jersey, USA
  • 2001-Present "Profesor Honorario" (Adjunct Professor), Department de Biochemistry and Molecular Biology, Universidad Autónoma, Madrid, Spain

PROFESSIONAL RECOGNITION

I. HONORARY APPOINTMENTS
  • Doctor Honoris Causa, Universidad Internacional Menéndez y Pelayo, Spain 1995
  • Honorary Member, Foundatión Guilé. Switzerland, 1999

II. OTHER APPOINTMENTS
  • Associated (foreign) EMBO Member, 1996
  • Regular EMBO Member since 1998
  • Member of Academia Europaea, since 2004
  • Founding Member, European Academy of Cancer Sciences, since 2009
  • Founding Member, European Research Institute for Integrated Cellular Pathology (ERI-ICP), since 2009

III. INTERNATIONAL AWARDS
  • Distinguished Young Scientist, Maryland Acad. Sciences, Baltimore, USA, 1983
  • Young Investigator Award, AACR, Los Angeles, USA,1986
  • Joseph Steiner Prize, Bern, Switzerland, 1988
  • Ipsen Prize, Paris, France 1994
  • XXXIV Jiménez Díaz Award, Madrid, Spain, 2002
  • Charles Rodolphe Brupbacher Cancer Prize, Zurich, Switzerland, 2005
  • "IARC Medal of Honour", IARC, WHO, Lyon, France, 2007

IV. SPANISH AWARDS
  • Spanish Association Against Cancer Award, Madrid, Spain1984
  • Francesc Duran-Reynals Award, Barcelona, Spain 1984
  • King Juan Carlos I Award, Madrid, Spain 1984
  • Marques de Valdecilla, Award, Santander, Spain 1987
  • Gold Medal, Foundation Garcia-Cabrerizo, Madrid, Spain 1995
  • X Carmen and Severo Ochoa Award, Madrid, Spain, 2003
  • Medal of Honour, Academy of Medicine and Surgery, Valladolid, Spain
  • “Distinguish Career Award”, Lilly Foundation, El Escorial, Spain, 2009

V. SPECIAL LECTURES
  • "Frontiers in Biology" Lecture, Case Western Reserve Univ., Cleveland, OH, 1994
  • "SmithKline Beecham Lecture on Health Sciences", University College of London, London, England, May 1994
  • "XIII Gerónimo Forteza Lecture", FVIB, Valencia, Spain, May 1994
  • IV Rita Levi-Montalcini Lecture”, II European Neuroscience Meeting, Strasbourg, France, September 1996
  • Muhlbock Memorial Lecture”, XVI Meeting of the European Association for Cancer Research (EACR), Thessaloniki, Greece, June 2000
  • "Pan American Biochemistry and Molecular Biology (PABMB) Special Lecture", FEBS Meeting, Brussels, July 2003
  • The Colin Thomson Memorial Lecture”, Association for International Cancer Research, Glasgow, June 2005
  • The Jack Gross Memorial Lecture”, The Hebrew University, Jerusalem, Israel. December 2005
  • "Roger Sohier Memorial Lecture", International Agency for Research on Cancer, Lyon, May 2007

VI. KEYNOTE SPEAKER:
  • X Congress of the Spanish Society of Biochemistry, September 1982
  • First Iberoamerican Congress of Oncology, November 1985
  • I Congress of the Spanish Federation of Oncological Societies, March 1990
  • XI Meeting of the Spanish Society of Pharmaceutical Industries, May 1990
  • XIX International Congress of Pathology, October 1992
  • Societat Catalana de Biología, October 1992
  • IV Spanish Congress of Medical Oncology, May 1993
  • V Congress of the Spanish Assoc. for Cancer Res., September 1993
  • Annual Meeting, The Cancer Institute of New Jersey, June 1995
  • VI Congress of the Spanish Assoc. for Cancer Res., 1995
  • XXVI Congress, Federation of European Biochem. Societies (FEBS), June 1999
  • Graduate School, Hartman Institute, University of Helsinki, September 2000
  • 15th European Congress of Clinical Chemistry and Lab. Medicine, June 2003
  • Seventh Global Novartis Oncology Research Meeting, June 2003
  • II Symposium on Anti-Receptor Signaling in Human Neoplasia, August 2003
  • II International Symposium IUOPA, November 2005
  • Joint ECCO 15th-34th ESMO Multidisplinary Congress, Berlin 2009
  • 2009 Frontiers in Cancer Science Symposium, Cancer Science Institute, Singapore

VII. MEETING ORGANIZER
  • First Annual Meeting on Oncogenes, Frederick, MD, 1985.
  • NATO Course "The Molecular Basis of Growth Regulation", Mallorca, Spain 1989.
  • Keystone Symp. "Phosphorylation on Signal Transduction", Keystone, CO, 1993.
  • Keystone Symp. “Signaling in Neuronal Development, Differentiation and Degeneration”, Taos, NM, 1995.
  • Foundation March, International Meeting on “Signal Transduction in Neuronal Development and Recognition”, Madrid, 1997.
  • III Symp. Lilly Foundation on “Molecular Targets for Novel Therapies” Madrid, 2003.
  • CNIO Cancer Conference on “Animal Tumor Models and Functional Genomics”, Madrid, 2005.
  • Nature-CNIO Symposium on "Human Oncogenes: The Next 25 Years", Madrid, 2007

EDITORIAL BOARDS
  • Cancer Research, 1986-1991
  • International Journal of Cancer, since 1985
  • Oncogene, 1986-2004
  • Cell Growth and Differentiation, since 1990
  • Seminars in Cancer Biology, since 1990
  • Journal of Biological Chemistry, 1995-2000
  • Molecular and Cellular Neuroscience, since 1997
  • EMBO Journal, since 1998
  • Molecular Cell Biology and Research Communications, since 1998
  • Microbiología SEM, since 1998
  • Archives of Biochemistry and Biophysics, 1999-2004
  • Encyclopedia of Cancer Research, since 1999
  • Predictive Oncology, since 1999
  • EMBO Reports, since 2000
  • International Journal of Oncology, since 2000.
  • Molecular Carcinogenesis, since 2000
  • The Journal of Antibiotics, since 2000
  • Journal of the National Cancer Institute, since 2001
  • Cancer Cell, since 2002
  • BioMed Central Cancer, since 2002
  • Genes, Chromosomes and Cancer, since 2003
  • Cell Division, since 2005
  • European Journal of Cancer, since 2005
  • Molecular Oncology, since 2007
  • Deputy Editor, Cancer Research, since 2007
  • Science Translational Medicine, since 2009

ADVISORY BOARDS (current appointments only)
  • Scientific Advisory Board, Foundation Ramon Areces, Madrid, Spain
  • Scientific Advisory Board, European Institute of Oncology, Milan, Italy
  • Scientific Advisory Board (President), Fundación Lilly, Madrid, Spain
  • Search Committee, Koerber European Science Award. Hamburg, Germany
  • Scientific Advisory Board, Mouse Clinical Institute (ICS), Strasbourg, France
  • Scientific Advisory Board, Canceropole Ile de France, Paris, France
  • Scientific Advisory Board. Depart. of Biomedicine, Univ. of Basel, Switzerland
  • Advisory Council, Cancer Research & Therap. Innov. Network, Toulouse, France
  • Review Board, Paterson Institute for Cancer Research, Manchester, UK
  • Board Advisory Group, MRC Cancer Cell Unit, Cambridge, UK

PROFESSIONAL SOCIETY MEMBERSHIPS
  • American Society for Biological Chemists
  • American Society for Microbiology
  • American Association for Cancer Research
  • European Association for Cancer Research
  • Spanish Society for Biochemistry and Molecular Biology (SEBBM)

PUBLICATION RECORD
  • To date, Dr. Barbacid has authored a total of 246 publications, including 177 original research articles in journals with impact factor, 24 invited reviews in refereed journals and 45 book chapters.
  • The average impact factor of the 201 papers and reviews published in referee journals is >12.
  • Currently, Dr. Barbacid's Hirsch "h" factor is 86.


BIOGRAPHY
Mariano Barbacid was born in Madrid, Spain in 1949. He got his Ph.D. degree in Biochemistry from the Universidad Complutense of Madrid in 1974. From 1974-1978 he trained as a postdoctoral fellow in retroviral oncogenes in the group of Stuart A. Aaronson at the National Cancer Institute in Bethesda, Maryland. In 1978 he started his own group to work on the molecular biology of human tumours. His work led to the isolation of the first human cancer gene (oncogene) in the spring of 1982. Subsequently, he demonstrated that this oncogene was a mutant allele of the H-Ras proto-oncogene and owed its oncogenic properties to a single somatic mutation in its coding sequences. These seminal findings, also made independently by the groups of Robert Weinberg (MIT) and Michael Wigler (CSHL), have played a key role in establishing the molecular bases of human cancer.

In 1984, Barbacid moved to the NCI-Frederick, Maryland as Head of the Developmental Oncology Section and in 1988, Barbacid joined the Bristol Myers-Squibb Pharmaceutical Research Institute in Princeton, New Jersey where he became Vice President, Oncology Drug Discovery in 1995. In 1998, he returned to his native Madrid to create the CNIO that currently houses 450 investigators allocated in twenty five research groups (see Commentary in Cell, 129: 641-644, 2007). Since his return to Spain, Barbacid is concentrating on the study of the role of cell cycle regulators in vivo and on the design of new animal models of cancer using gene-targeting technologies.

Other contributions of special scientific relevance include the identification of Ras oncogenes as targets of chemical carcinogens (1984-85), the discovery of the Trk family of tyrosine protein kinase receptors (1985-88) and the subsequent demonstration that they are the signalling receptors for the NGF family of neurotrophic factors (1991) More recently (2003-07), the Barbacid lab has demonstrated that mammalian Cdks are not essential for driving the specific phases of the cell cycle but to sustain proliferation of specialized cell types. These observations have led to draw a new model for the mammalian cell cycle.

The relevance of his work has been recognised by several awards, including the Young Investigator Award of the American Association of Cancer Research (USA, 1986), Steiner Prize (Switzerland, 1988), Ipsen Prize in Neurobiology (France, 1994), the Brupbaher Cancer Research Prize (Switzerland, 2005) and the Medal of Honour of the International Agency for Cancer Research (WHO) (Lyon 2007). In addition, Barbacid has received several Spanish Awards and a Doctorate Honoris causa by the Universidad Internacional Menendez y Pelayo (1995). He is a Member of EMBO since 1996.

Imprint Privacy policy « This page (revision-12) was last updated on Wednesday, 11. January 2017, 14:59 by Kaiser Dana
  • operated by